# Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients

> **NCT06442709** · NA · UNKNOWN · sponsor: **Affiliated Hospital of Nantong University** · enrollment: 100 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Tocilizumab Asprin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06442709
- **Lead sponsor:** Affiliated Hospital of Nantong University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-01
- **Primary completion:** 2024-07-01
- **Final completion:** 2024-07-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06442709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06442709, "Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06442709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*